Abstract
Abbreviations and Acronyms:
iPS (induced pluripotent stem cell)- 1.Read the activity.
- 2.Complete the online CME Test and Evaluation. Participants must achieve a score of 80% on the CME Test. One retake is allowed.
There's no finish line in the work of science … the urgent work of giving substance to hope, of seeking a day when words like ‘terminal' and ‘incurable' are potentially retired from our vocabulary….
President Barack Obama1The White House. Signing of stem cell executive order and scientific integrity presidential memorandum: remarks of President Barack Obama. http://www.whitehouse.gov/the_press_office/Remarks-of-the-President-As-Prepared-for-Delivery-Signing-of-Stem-Cell-Executive-Order-and-Scientific-Integrity-Presidential-Memorandum. Accessed February 10, 2013.
US Department of Health and Human Services. 2020: A new vision—a future for regenerative medicine. http://medicine.osu.edu/regenerativemedicine/documents/2020vision.pdf. Accessed February 10, 2013.
Unmet Needs in the 21st Century: Chronic Disease in an Aging Population
World Health Organization. Global status report on noncommunicable diseases 2010. http://www.who.int/chp/ncd_global_status_report/en/index.html. Accessed February 10, 2013.
World Health Organization. Global health observatory (GHO): noncommunicable diseases (NCD). http://www.who.int/gho/ncd/en/index.html. Accessed February 10, 2013.
United Nations Population Fund and HelpAge International. Ageing in the 21st century: a celebration and a challenge. http://unfpa.org/ageingreport. Accessed February 10, 2013.
United Nations Population Fund and HelpAge International. Ageing in the 21st century: a celebration and a challenge. http://unfpa.org/ageingreport. Accessed February 10, 2013.
Regenerative Medicine Proposition
Organ Procurement and Transplantation Network. Waiting list candidates. http://optn.transplant.hrsa.gov. Accessed February 10, 2013.
Stem Cell and Tissue Engineering Toolkits
Natural Stem Cells
US Food and Drug Administration. FDA approves first cord blood product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279575.htm. Accessed February 10, 2013.
Bioengineered Stem Cells
Regenerative Material Sciences
Regenerative Medicine at Point of Care
Regenerative Medicine Future
Conclusion
Supplemental Online Material
References
The White House. Signing of stem cell executive order and scientific integrity presidential memorandum: remarks of President Barack Obama. http://www.whitehouse.gov/the_press_office/Remarks-of-the-President-As-Prepared-for-Delivery-Signing-of-Stem-Cell-Executive-Order-and-Scientific-Integrity-Presidential-Memorandum. Accessed February 10, 2013.
US Department of Health and Human Services. 2020: A new vision—a future for regenerative medicine. http://medicine.osu.edu/regenerativemedicine/documents/2020vision.pdf. Accessed February 10, 2013.
- Regenerative medicine advancing health care 2020.J Am Coll Cardiol. 2010; 55: 2254-2257
- Strategies for therapeutic repair: the R3 regenerative medicine paradigm.Clin Transl Sci. 2008; 1: 168-171
- Regenerative medicine: on the vanguard of health care.Mayo Clin Proc. 2011; 86: 600-602
World Health Organization. Global status report on noncommunicable diseases 2010. http://www.who.int/chp/ncd_global_status_report/en/index.html. Accessed February 10, 2013.
- Chronic diseases: the emerging pandemic.Clin Transl Sci. 2011; 4: 225-226
World Health Organization. Global health observatory (GHO): noncommunicable diseases (NCD). http://www.who.int/gho/ncd/en/index.html. Accessed February 10, 2013.
- Cardiovascular health: the global challenge.Clin Pharmacol Ther. 2011; 90: 483-485
United Nations Population Fund and HelpAge International. Ageing in the 21st century: a celebration and a challenge. http://unfpa.org/ageingreport. Accessed February 10, 2013.
- From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.Clin Pharmacol Ther. 2011; 90: 509-518
- Aging and cardioprotection.J Appl Physiol. 2007; 103: 2120-2128
- Knowledge cycle transforms therapeutic innovation.Clin Pharmacol Ther. 2012; 91: 3-8
Organ Procurement and Transplantation Network. Waiting list candidates. http://optn.transplant.hrsa.gov. Accessed February 10, 2013.
- Organ transplantation: how much of the promise has been realized?.Nat Med. 2005; 11: 605-613
- Lab-grown organs seen as remedy for long donor waitlists.Nat Med. 2010; 16: 834
- Strategies for homeostatic stem cell self-renewal in adult tissues.Cell. 2011; 145: 851-862
- Regenerating new heart with stem cells.J Clin Invest. 2013; 123: 62-70
- Evidence for cardiomyocyte renewal in humans.Science. 2009; 324: 98-102
- Stem cell platforms for regenerative medicine.Clin Transl Sci. 2009; 2: 222-227
- Printing and prototyping of tissues and scaffolds.Science. 2012; 338: 921-926
- Induced pluripotent stem cells: developmental biology to regenerative medicine.Nat Rev Cardiol. 2010; 7: 700-710
- Regenerative medicine and stem cell therapeutics.in: Waldman S.A. Terzic A. Pharmacology and Therapeutics: Principles to Practice. Saunders, Elsevier, Philadelphia, PA2009: 1317-1331
- Cardiac cell repair therapy: a clinical perspective.Mayo Clin Proc. 2009; 84: 876-892
- Cells as biologics for cardiac repair in ischaemic heart failure.Heart. 2010; 96: 792-800
- Stem cells: biologics for regeneration.Clin Pharmacol Ther. 2008; 84: 620-623
- Paracrine mechanisms in adult stem cell signaling and therapy.Circ Res. 2008; 103: 1204-1219
- Stem cells: clinical trials results the end of the beginning or the beginning of the end?.Cardiovasc Hematol Disord Drug Targets. 2010; 10: 186-201
- Embryonic stem cell lines derived from human blastocysts.Science. 1998; 282: 1145-1147
- Expanding the boundaries of embryonic stem cells.Cell Stem Cell. 2012; 10: 666-677
- Embryonic stem cell trials for macular degeneration: a preliminary report.Lancet. 2012; 379: 713-720
- Embryonic stem cells for severe heart failure: why and how?.J Cardiovasc Transl Res. 2012; 5: 555-565
- Umbilical cord blood transplantation: the first 20 years.Semin Hematol. 2010; 47: 3-12
US Food and Drug Administration. FDA approves first cord blood product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279575.htm. Accessed February 10, 2013.
- Umbilical cord blood stem cells: clinical trials in non-hematological disorders.Br Med Bull. 2012; 102: 43-57
- Stem cell transplantation in inherited metabolic disorders.Hematology Am Soc Hematol Educ Program. 2011; 2011: 285-291
- Umbilical cord blood transplantation and banking.Annu Rev Med. 2006; 57: 403-417
- The cord-blood-bank controversies.N Engl J Med. 2004; 351: 2255-2257
- Adult stem cells for tissue repair: a new therapeutic concept?.N Engl J Med. 2003; 349: 570-582
- The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine.Nat Med. 2013; 19: 35-42
- Hematopoietic stem-cell transplantation.N Engl J Med. 2006; 354: 1813-1826
- Autologous hematopoietic stem-cell transplantation for multiple myeloma.N Engl J Med. 2009; 360: 2645-2654
- Current status of stem cell mobilization.Br J Haematol. 2010; 150: 647-662
- Hematopoietic cell transplantation for nonmalignant disorders.Biol Blood Marrow Transplant. 2012; 18: S166-S171
- Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases.JAMA. 2008; 299: 925-936
- Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability.Cell Transplant. 2011; 20: 797-811
- Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.Cell Stem Cell. 2012; 10: 244-258
- Mesenchymal stem cells for bone repair and metabolic bone diseases.Mayo Clin Proc. 2009; 84: 893-902
- Therapeutic applications of mesenchymal stem cells: current outlook.BioDrugs. 2012; 26: 201-208
- Mesenchymal stromal cell therapy: a revolution in regenerative medicine?.Bone Marrow Transplant. 2012; 47: 164-171
- Clinical applications of mesenchymal stem cells.J Hematol Oncol. 2012; 5: 19
- Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders.Ann N Y Acad Sci. 2012; 1266: 107-117
- Mesenchymal stromal cells: new directions.Cell Stem Cell. 2012; 10: 709-716
- Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction.J Am Coll Cardiol. 2010; 56: 721-734
- Cardiopoietic stem cell therapy in heart failure: the C-CURE multicenter randomized trial with lineage-specified biologics.J Am Coll Cardiol. 2013; 61: 2329-2338
- Cellular alchemy and the golden age of reprogramming.Cell. 2012; 151: 1151-1154
- Nuclear reprogramming in cells.Science. 2008; 322: 1811-1815
- Nuclear reprogramming to a pluripotent state by three approaches.Nature. 2010; 465: 704-712
- Induced pluripotent stem cells: past, present, and future.Cell Stem Cell. 2012; 10: 678-684
- Metabolic plasticity in stem cell homeostasis and differentiation.Cell Stem Cell. 2012; 11: 596-606
- Energy metabolism plasticity enables stemness programs.Ann N Y Acad Sci. 2012; 1254: 82-89
- The science and ethics of induced pluripotency: what will become of embryonic stem cells?.Mayo Clin Proc. 2011; 86: 634-640
- Induced pluripotent stem cells: advances to applications.Stem Cells Cloning. 2010; 3: 29-37
- Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk.Stem Cells Transl Med. 2012; 1: 709-718
- Induced pluripotent stem cells: a cautionary note.N Engl J Med. 2011; 364: 2160-2162
- Human induced pluripotent stem cells: the past, present, and future.Clin Pharmacol Ther. 2011; 89: 741-745
- The promise of induced pluripotent stem cells in research and therapy.Nature. 2012; 481: 295-305
- Induced pluripotent stem cells: the new patient?.Nat Rev Mol Cell Biol. 2012; 13: 713-726
- Reprogrammed cells for disease modeling and regenerative medicine.Annu Rev Med. 2013; 64: 277-290
- The use of induced pluripotent stem cells in drug development.Clin Pharmacol Ther. 2011; 89: 655-661
- Induced pluripotent stem cells: an emerging theranostics platform.Clin Pharmacol Ther. 2011; 89: 648-650
- Nanotechnological strategies for engineering complex tissues.Nat Nanotechnol. 2011; 6: 13-22
- Designing cell-compatible hydrogels for biomedical applications.Science. 2012; 336: 1124-1128
- Unlike bone, cartilage regeneration remains elusive.Science. 2012; 338: 917-921
- Composite scaffold provides a cell delivery platform for cardiovascular repair.Proc Natl Acad Sci U S A. 2011; 108: 7974-7979
- Bioengineering heart muscle: a paradigm for regenerative medicine.Annu Rev Biomed Eng. 2011; 13: 245-267
- Tissue engineering on matrix: future of autologous tissue replacement.Semin Immunopathol. 2011; 33: 307-315
- Regeneration and orthotopic transplantation of a bioartificial lung.Nat Med. 2010; 16: 927-933
- Organ engineering based on decellularized matrix scaffolds.Trends Mol Med. 2011; 17: 424-432
- Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction.J Am Coll Cardiol. 2012; 59: 751-763
- Engineered whole organs and complex tissues.Lancet. 2012; 379: 943-952
- Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart.Nat Med. 2008; 14: 213-221
- Tissue-engineered lungs for in vivo implantation.Science. 2010; 329: 538-541
- Tissue-engineered airway: a regenerative solution.Clin Pharmacol Ther. 2012; 91: 81-93
- Moving towards in situ tracheal regeneration: the bionic tissue engineered transplantation approach.J Cell Mol Med. 2010; 14: 1877-1889
- Engineering complex tissues.Sci Transl Med. 2012; 4: 160rv12
- Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.Lancet. 2011; 378: 1997-2004
- Bioprinting towards organ fabrication: challenges and future trends.IEEE Trans Biomed Eng. 2013; 60: 691-699
- Bioprinting for stem cell research.Trends Biotechnol. 2013; 31: 10-19
- Defeating stem cell tourism.Regen Med. 2010; 5: 681-686
- Regulating autologous adult stem cells: the FDA steps up.Cell Stem Cell. 2011; 9: 393-396
- Stem cell therapies could change medicine ... if they get the chance.Cell Stem Cell. 2012; 10: 663-665
- The Alpha Stem Cell Clinic: a model for evaluating and delivering stem cell-based therapies.Stem Cells Transl Med. 2012; 1: 9-14
- Cardiac stem cell therapies inch toward clinical litmus test.Nat Biotechnol. 2013; 31: 5-6
- Regenerative medicine: a reality of stem cell technology.Minn Med. 2011; 94: 44-47
- Collection, processing, and banking of umbilical cord blood stem cells for transplantation and regenerative medicine.Methods Mol Biol. 2012; 879: 279-290
- Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities.Stem Cells. 2012; 30: 55-60
- Infrastructure development for human cell therapy translation.Clin Pharmacol Ther. 2007; 82: 320-324
- Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010.Regen Med. 2010; 5: 307-313
- Cell therapies for liver diseases.Liver Transpl. 2012; 18: 9-21
- New strategies to optimize kidney recovery and preservation in transplantation.Nat Rev Nephrol. 2012; 8: 339-347
- Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.JAMA. 2012; 307: 1169-1177
- Stem cell-based therapy and regenerative approaches to diseases of the respiratory system.Br Med Bull. 2011; 99: 169-187
- Perspectives on whole-organ assembly: moving toward transplantation on demand.J Clin Invest. 2012; 122: 3817-3823
Article Info
Footnotes
For editorial comment, see page 645.
Individual reprints of this article and a bound reprint of the entire Symposium on Regenerative Medicine will be available for purchase from our website http://www.mayoclinicproceedings.org.
The Symposium on Regenerative Medicine will continue in an upcoming issue.